Synthesis of C3 heteroatom-substituted azetidinones that display potent cholesterol absorption inhibitory activity

Journal of Medicinal Chemistry

Volumn 41, Issue 5, 1998, Pages 752-759

  McKittrick, Brian A ^a   Ma, Ke ^a   Huie, Keith ^a   Yumibe, Nathan ^a   Davis Jr , Harry ^a   Clader, John W ^a   Czarniecki, Michael ^a   McPhail, Andrew T ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 BIS(4 METHOXYPHENYL) 3 (3 PHENYLPROPYL) 2 AZETIDINONE; 3 (1 HYDROXY 3 PHENYLPROPYL) 4 (4 METHOXYPHENYL) 1 PHENYL 2 AZETIDINONE; 3 (3 HYDROXY 3 PHENYLPROPYL) 4 (4 METHOXYPHENYL) 1 PHENYL 2 AZETIDINONE; AZETIDINONE DERIVATIVE; CHOLESTEROL ESTER; HYPOCHOLESTEROLEMIC AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHOLESTEROL INTAKE; CHOLESTEROL LIVER LEVEL; DRUG ACTIVITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; MALE; MONKEY; NONHUMAN; ORAL DRUG ADMINISTRATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BILE; CHOLESTEROL; INTESTINAL ABSORPTION; MACACA FASCICULARIS; MALE; MOLECULAR STRUCTURE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032568092     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm970676d     Document Type: Article

References (14)

1. Burnett, D. A.; Caplen, M. A.; Davis, H. R., Jr.; Burner, R. E.; Clader, J. W. 2-Azetidinones as inhibitors of cholesterol absorption. J. Med. Chem. 1994, 37, 1733-1736. For related recent work in this area, see: Clader, J. W.; Burnett, D. A.; Caplen, M. A.; Domalski, M. S.; Dugar, S.; Vaccaro, W.; Sher, R.; Browne, M. E.; Zhao, H.; Burner, R. E.; Salisbury, B.; Davis, H. R., Jr. 2-Azetidinone cholesterol absorption inhibitors: Structure-activity relationships on the heterocyclic nucleus. J. Med. Chem. 1996, 39, 3684-3693. Rosenblum, S. B.; Huynh, T.; Afonso, A.; Davis, H. R., Jr.; Yumibe, N.; Clader, J. W.; Burnett, D. A. Discovery of SCH 58235: A designed potent orally active inhibitor of cholesterol absorption. J. Med. Chem. 1998, submitted.
2. Burnett, D. A.; Caplen, M. A.; Davis, H. R., Jr.; Burner, R. E.; Clader, J. W. 2-Azetidinones as inhibitors of cholesterol absorption. J. Med. Chem. 1994, 37, 1733-1736. For related recent work in this area, see: Clader, J. W.; Burnett, D. A.; Caplen, M. A.; Domalski, M. S.; Dugar, S.; Vaccaro, W.; Sher, R.; Browne, M. E.; Zhao, H.; Burner, R. E.; Salisbury, B.; Davis, H. R., Jr. 2-Azetidinone cholesterol absorption inhibitors: Structure-activity relationships on the heterocyclic nucleus. J. Med. Chem. 1996, 39, 3684-3693. Rosenblum, S. B.; Huynh, T.; Afonso, A.; Davis, H. R., Jr.; Yumibe, N.; Clader, J. W.; Burnett, D. A. Discovery of SCH 58235: A designed potent orally active inhibitor of cholesterol absorption. J. Med. Chem. 1998, submitted.
3. Burnett, D. A.; Caplen, M. A.; Davis, H. R., Jr.; Burner, R. E.; Clader, J. W. 2-Azetidinones as inhibitors of cholesterol absorption. J. Med. Chem. 1994, 37, 1733-1736. For related recent work in this area, see: Clader, J. W.; Burnett, D. A.; Caplen, M. A.; Domalski, M. S.; Dugar, S.; Vaccaro, W.; Sher, R.; Browne, M. E.; Zhao, H.; Burner, R. E.; Salisbury, B.; Davis, H. R., Jr. 2-Azetidinone cholesterol absorption inhibitors: Structure-activity relationships on the heterocyclic nucleus. J. Med. Chem. 1996, 39, 3684-3693. Rosenblum, S. B.; Huynh, T.; Afonso, A.; Davis, H. R., Jr.; Yumibe, N.; Clader, J. W.; Burnett, D. A. Discovery of SCH 58235: A designed potent orally active inhibitor of cholesterol absorption. J. Med. Chem. 1998, submitted.
4. 1 had demonstrated only weak ACAT activity for a series of structurally related azetidinones. Therefore it is highly unlikely that the weak ACAT activity that these compounds may have would account for the potent CAI activity observed.
5. Bergman, M.; Morales, H.; Meilars, L.; Kosoglou, T.; Burner, R.; Davis, H. R.; Sybertz, E. J.; Pollare, T. The clinical development of a novel cholesterol absorption inhibitor. 12th International Symposium on Drugs Affecting Lipid Metabolism, 1995.
6. McKittrick, B. A.; Ma, K.; Dugar, S.; Clader, J. W.; Davis, H., Jr.; Czarniecki, M.; McPhail, A. T. Stereoselective synthesis and biological activity of cis azetidinones as cholesterol absorption inhibitors. Bioorg. Med. Chem. Lett. 1996, 6, 1947-1950.
7. Rosenblum, S. B.; Huynh, T.; Davis, H.; Yumibe, N.; Clader, J.; Afonso, A.; Burnett, D. B. International Symposium on Drugs Affecting Lipid Metabolism, 1995.
8. Van Heek, M.; France, C. F.; Compton, D. S.; McLeod, R. L.; Yumibe, N. P.; Alton, K. B.; Sybertz, E. J.; Davis, H. R In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH 58235, in the rat and Rhesus monkey through the identification of the active metabolites of SCH 48461. JPET 1997, 283, 157-163.
9. Dugar, S.; Yumibe, N.; Clader, J. W.; Vizziano, M.; Huie, K.; Van Heek, M.; Compton, D. S.; Davis, H. R., Jr. Metabolism and structure activity data based drug design: Discovery of (-) SCH 53079 an analogue of the potent cholesterol absorption inhibitor (-) SCH 48461. Bioorg. Med. Chem. Lett. 1996, 6, 2069-2073
10. Thiruvendagam, T. K.; Tann, C. H.; McAllister, T. L. Process for the stereospecific synthesis of azetidinones. U.S. Patent 5561227.
11. Evans, D. A.; Urpi, F.; Somers, T. C.; Clark, J. S.; Bilodeau, M. T. New procedure for the direct generation of titanium enolates. Diastereoselective bond constructions with representative electrophiles. J. Am. Chem. Soc. 1990, 112, 8215-8216.
12. Drabrowicz, J.; Dudzinski, B.; Mikolajczyk, M. Sulfonic acidsodium iodide system as an efficient reagent for the reduction of sulfoxides. Synlett 1992, 252-254.
13. Pridgen, L. N.; Abdel-Magid, A.; Lantos, I.; Shilcrat, S.; Eggleston, D. Chelation control in metal-assisted aldol reactions of α-halogenated imide enolates leading to predominately anti stereoselectivity. An example of a stereocontrolled Darzens reaction. J. Org. Chem. 1993, 55, 5107.
14. Schwartz, N. N.; Blumbergs, J. H. Epoxidations with m-CPBA. J. Org. Chem. 1964, 29, 1976-1979.